1. Каталог >
  2. Клетки, микроорганизмы, среды >
  3. Клеточные линии >
  4. Клеточные линии по типам >
  5. Скелетная мускулатура: клетки >

Клетки скелетной мускулатуры человека: HSkMC. Первичные клеточные линии Cell Applications.

Human Skeletal Muscle Cells: HSkMC

Клетки Скелетной Мускулатуры Человека (HSkMC), выделенные из взрослых или эмбриональных конечностей, положительные на миозин саркомеров и  могут затем дифференцироваться, проявляя актиновые и миозиновые миофиламенты. Клетки HSkMC предоставляют удобную систему для изучения многих аспектов функций и заболеваний мускулатуры и могут служить как  вспомогательная модель заболеваний человека. Клетки скелетной мускулатуры также играют важную роль в метаболизме глюкозы и диабете. Вы можете дополнительно выбрать протестированный набор клеток от Cell Applications, Inc. для демонстрации сигналинга AMPK и отзывчивость к стимуляции инсулином.

HSkMC от Cell Applications, Inc. были использованы для:

(Текст на языке оригинала)
  • Serve as a differentiated control in a study of developmental regulator genes in hESC
  • Characterize statin-induced gene expression changes and demonstrate cytotoxic effect of statins in skeletal muscle cells
  • Identify molecular mechanisms of mitochondrial myopathy and sideroblastic anemia resulting from a missense mutation in the PUS1 gene
  • Investigate chemokine-like factor expression in the idiopathic inflammatory myopathies
  • Demonstrate that fasting activates AceCS2 gene expression by inducing KLF15 transcription factor
  • Characterize human FGFR3-positive sarcoma-initiating stem cells
  • Identify trans-Golgi network proteins and Notch and Hedgehog pathways as putative targets for rhabdomyosarcoma therapy
  • Show that riluzole muscle relaxant effects are mediated by inhibition of INa and stimulation of BKC-channel activity
  • Develop nitric esters that combine the pharmacological functions of NO and muscle relaxation properties for treatment of muscular diseases
  • Develop biodegradable polymer-based transgene delivery vectors for muscular dystrophy treatment
  • Design optimal coating for orthopedic metallic implants

Параметры

Tissue:
Normal human limb skeletal muscle.  Each lot is tested negative for HIV, Hepatitis B, Hepatitis C, mycoplasma, bacteria, and fungi.
Cryopreserved ampoule:
2nd passage, >500,000 cells in Basal Medium containing 10% FBS & 10% DMSO.
Kit contains:
Ampoule of cryopreserved HSkMC (150-05), 500 ml of HSkMC Growth Medium (151-500), and a Subculture Reagent Kit (090K).
Proliferating Cells:
Shipped in Transfer Medium at 3rd passage in either flasks or multiwell dishes.
Population doublings:
Can be cultured at least 15 doublings


Документы



Публикации

2016
Duncan, D., T. Kamerzell and M. Palmer. 2016. Use of Indole Compounds for Fat Reduction and Skin and Soft Tissue Tightening.  Patent Applications US 20160030389 A1.
2014
Iizuka, K., T. Machida, and M. Hirafuji. 2014. Extracellular MCT4 Is a Possible Indicator for Skeletal Muscle MHC Fiber Type Change. Ann Clin Lab Sci, 44:272-276.
2013
Wang, G., and Q. Lu. 2013. A nitrate ester of sedative alkyl alcohol improves muscle function and structure in a murine model of Duchenne muscular dystrophy. Molecular pharmaceutics. 10:3862-3870.
2012
Idris, N., M. Ashraf, R. Ahmed, J. Shujia, and K. Haider. 2012. Activation of IL-11/STAT3 pathway in preconditioned human skeletal myoblasts blocks apoptotic cascade under oxidant stress. Regen Med, 7:47-57.
Nagao, H., T. Setoguchi, S. Kitamoto, Y. Ishidou, S. Nagano, M. Yokouchi, M. Abematsu, N. Kawabata, S. Maeda, S. Yonezawa, and S. Komiya. 2012. RBPJ Is a Novel Target for Rhabdomyosarcoma Therapy. PloS one. 7:e39268.
Wang, M., J.D. Tucker, P. Lu, B. Wu, C. Cloer, and Q. Lu. 2012. Tris[2-(acryloyloxy)ethyl]isocyanurate Cross-Linked Low-Molecular-Weight Polyethylenimine as Gene Delivery Carriers in Cell Culture and Dystrophic mdx Mice. Bioconjugate chemistry. 23:837-845.
2011
Kawabata, N., K. Ijiri, Y. Ishidou, T. Yamamoto, H. Nagao, S. Nagano, S. Maeda, S. Komiya, and T. Setoguchi. 2011. Pharmacological inhibition of the Hedgehog pathway prevents human rhabdomyosarcoma cell growth. International journal of oncology. 39:899.
Kunigou, O., H. Nagao, N. Kawabata, Y. Ishidou, S. Nagano, S. Maeda, S. Komiya, and T. Setoguchi. 2011. Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncology reports. 26:1337-1342.
2010
Thuangtong, R., J.J. Bentow, K. Knopp, N.A. Mahmood, N.E. David, and M.S. Kolodney. 2010. TissueSelective Effects of Injected Deoxycholate. Dermatologic Surgery. 36:899-908.
Zalevsky, J., D. Nguyen, G. Moore, S. Ezhevsky, J. Desjarlais, A. Chirino, D. Cash, and M. Bernett. 2010. Pharmaceutical compositions of adiponectin variants and methods of storage. Patent US 7678886 B2.
Zalevsky, J., D. Nguyen, G. Moore, S. Ezhevsky, J. Desjarlais, A. Chirino, D. Cash, and M. Bernett. 2010. Adiponectin variants. Patent US 7709607 B2.
Zalevsky, J., D. Nguyen, G. Moore, S. Ezhevsky, J. Desjarlais, A. Chirino, D. Cash, and M. Bernett. 2010. Method of treatment using adiponectin variants. Patent US 7749956 B2.
2009
Gupta, A., C. Lobocki, S. Singh, M. Robertson, O.A. Akadiri, G. Malhotra, and I.T. Jackson. 2009. Actions and Comparative Efficacy of Phosphatidylcholine Formulation and Isolated Sodium Deoxycholate for Different Cell Types. Aesth Plast Surg. 33:346-352.
Hirotsu, M., T. Setoguchi, Y. Matsunoshita, H. Sasaki, H. Nagao, H. Gao, K. Sugimura, and S. Komiya. 2009. Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer. 101:2030-2037.
Peters, L., and T. Lorenz. 2009. Postsynaptically Targeted Chemodenervation Agents and Their Methods of Use. Patent Application US 20110118190 A1.
Xu, J., S. Ekins, M. McGlashen, and D. Lauffenburger. 2009. FUTURE PERSPECTIVES OF BIOLOGICAL ENGINEERING IN PHARMACEUTICAL RESEARCH: THE PARADIGM OF MODELING, MINING, MANIPULATION, AND MEASUREMENTS. Ch. 14 inXu, J. and Ekins, S. 2009. Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools.
Xu, J. and L. Yu. 2009. Focus on the Fundamentals: Toward Better Therapeutic Index Prediction. Pg 19.  In: Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools.  Ekins S. and X Jinghai, Eds. John Wiley & Sons, Inc.
Zalevsky, J., D. Nguyen, G. Moore, S. Ezhevsky, J. Desjarlais, A. Chirino, D. Cash, and M. Bernett. 2009. Globular adiponectin variants. Patent US 7592423 B2.
2008
Wang, Y.-J., M.-W. Lin, A.-A. Lin, and S.-N. Wu. 2008. Riluzole-induced block of voltage-gated Na+ current and activation of BKCa channels in cultured differentiated human skeletal muscle cells. Life sciences. 82:11-20.
2006
Cash, D., A. Chirino, J. Desjarlais, S. Ezhevsky, G. Moore, D. Nguyen, and J. Zalevsky. 2006. Adiponectin variants. Patent Application US 20070015909 A1.
Perla, V., and T.J. Webster. 2006. nano-hydroxyapatite–thermally denatured small intestine sub-mucosa composites for entheses applications. International Journal of nanomedicine. 1:351.
Yamazaki, H., M. Suzuki, T. Aoki, S. Morikawa, T. Maejima, F. Sato, K. Sawanobori, M. Kitahara, T. Kodama, and Y. Saito. 2006. Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ubiquinone levels in rat skeletal muscle and heart: relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells. Journal of atherosclerosis and thrombosis. 13:295-307.
Zalevsky, J., D. Nguyen, G. Moore, S. Ezhevsky, J. Desjarlais, A. Chirino, D. Cash, and M. Bernett. 2006. Rational Chemical Modification of Adiponectin Variants. Patent Application US 20070054359 A1.
2005
Morikawa, S., T. Murakami, H. Yamazaki, A. Izumi, Y. Saito, T. Hamakubo, and T. Kodama. 2005. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J. atherosclerosis & thrombosis. 12:121-131.
Patton, J.R., Y. Bykhovskaya, E. Mengesha, C. Bertolotto, and N. Fischel-Ghodsian. 2005. Mitochondrial Myopathy and Sideroblastic Anemia (MLASA): Missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation. J. Biological Chemistry. 280:19823-19828.
Perla, V., M. Sato, and T.J. Webster. 2005. Increased Skeletal Muscle Cell and Osteoblast Numbers on Hydrothermally-Treated Nano-Hydroxyapatite/Collagen Type I Composites for Entheses Applications. Journal of Biomedical Nanotechnology. 1:297-305.
2004
Yamamoto, J., Y. Ikeda, H. Iguchi, T. Fujino, T. Tanaka, H. Asaba, S. Iwasaki, R.X. Ioka, I.W. Kaneko, K. Magoori, S. Takahashi, T. Mori, H. Sakaue, T. Kodama, M. Yanagisawa, T.T. Yamamoto, S. Ito, and J. Sakai. 2004. A Krüppel-like factor KLF15 Contributes Fasting-induced Transcriptional Activation of Mitochondrial Acetyl-CoA Synthetase Gene AceCS2. Journal of Biological Chemistry. 279:16954-16962.


НазваниеКодЦена
For general cryopreservation of most primary cells. Contains FBS & DMSO. 040-50 6228.74 руб.



НазваниеКодЦена
HSkMC Total Kit: Media, Subculture Reagents & Cells, Adult 150K-05a 99161.83 руб.
HSkMC Total Kit: Media, Subculture Reagents & Cells, Fetal 150K-05f 99161.83 руб.



НазваниеКодЦена
HSkMC Total Kit: Media, Subculture Reagents & Cells, Pre-Screened, Adult S150K-05a 117225.71 руб.
HSkMC Total Kit: Media, Subculture Reagents & Cells, Pre-Screened, Fetal S150K-05f 109750.96 руб.



НазваниеКодЦена
Cryopreserved HSkMC 150-05a 80351.28 руб.



НазваниеКодЦена
Cryopreserved HSkMC S150-05a 98414.49 руб.



НазваниеКодЦена
Cryopreserved HSkMC 150-05f 80351.28 руб.



НазваниеКодЦена
Cryopreserved HSkMC S150-05f 90940.41 руб.



НазваниеКодЦена
Cryopreserved HSkMC from donor with Type 2 Diabetes 150T2D-05a 88448.37 руб.



НазваниеКодЦена
HSkMC Total Kit: Media, Subculture Reagents & Cells from donor with Type 2 Diabetes, Adult 150T2DK-05a 107259.6 руб.



НазваниеКодЦена
Proliferating HSkMC 151-25a 80351.28 руб.
Proliferating HSkMC 151-75a 104020.9 руб.
Proliferating HSkMC 151-6Wa 104020.9 руб.
Proliferating HSkMC 151-96Wa 118969.73 руб.



НазваниеКодЦена
Proliferating HSkMC S151-96wa 149490.42 руб.
Proliferating HSkMC S151-6wa 122084.1 руб.
Proliferating HSkMC S151-25a 98414.49 руб.
Proliferating HSkMC S151-75a 122084.1 руб.



НазваниеКодЦена
Proliferating HSkMC 151-6Wf 100906.53 руб.
Proliferating HSkMC 151-96Wf 115855.36 руб.
Proliferating HSkMC 151-25f 80351.28 руб.
Proliferating HSkMC 151-75f 100906.53 руб.



НазваниеКодЦена
Proliferating HSkMC S151-96wf 129558.86 руб.
Proliferating HSkMC S151-25f 90940.41 руб.
Proliferating HSkMC S151-75f 114609.34 руб.
Proliferating HSkMC S151-6wf 114609.34 руб.



НазваниеКодЦена
Basal medium (contains no growth supplement).В  Add GS before use. 150-500 7225.42 руб.



НазваниеКодЦена
Promotes cells to change from one type to another, more specialized 151D-250 8097.09 руб.



НазваниеКодЦена
All-in-one ready-to-use 151-500 13703.5 руб.



НазваниеКодЦена
Added to Basal Medium to create Growth Medium 151-GS 7599.09 руб.



НазваниеКодЦена
100 ml each of HBSS, Trypsin/EDTA & Trypsin Neutralizing Solution 090K 6353.07 руб.



Extended Family Products

НазваниеКодЦена
100 tests 028-S 4152.49 руб.
500 tests 028-01 16070.53 руб.



НазваниеКодЦена
Total RNA prepared from Human Skeletal Muscle Cells, adult 150-R25a 80974.29 руб.
Total RNA prepared from Human Skeletal Muscle Cells, adult 150-R10aВ по запросу
Total RNA prepared from Human Skeletal Muscle Cells, Differentiated, fetal 150D-R10f 52321.95 руб.
Total RNA prepared from Human Skeletal Muscle Cells, Differentiated, fetal 150D-R25f 104643.23 руб.
Total RNA prepared from Human Skeletal Muscle Cells, fetal 150-R10f 40486.8 руб.
Total RNA prepared from Human Skeletal Muscle Cells, fetal 150-R25f 80974.29 руб.



НазваниеКодЦена
Total RNA prepared from human skeletal muscle tissue 1H60-250 60419.04 руб.
Total RNA prepared from human skeletal muscle tissue 1H60-50 16039.28 руб.



Related Products

НазваниеКодЦена
Basal medium & growth supplement sold together packaged separately 151K-500 14824.51 руб.




Информация представлена исключительно в ознакомительных целях и ни при каких условиях не является публичной офертой